1INTRODUCTIONAnemia is common in patients with malignancy. Ludwig et al. performed a prospective survey in 15,367 European cancer patients, and found that at enrolment, the overall prevalence of anemia was 39.3% and patients who received chemotherapy had the highest incidence of anemia at 62.7%. Anemia in cancer patients is multifactorial; nutritional deficiencies (iron, vitamin B12 and folate) are important etiologies.Iron deficiency anemia is one of the commonest forms of nutritional anemia, characterized by inadequate iron stores. Iron deficiency can be a true or functional deficiency. The standard therapy for iron deficiency anemia is iron supplementation, most commonly by oral iron supplements. The established indications for parenteral, that is intravenous (IV) iron supplementation include failure of oral iron, intolerance to oral iron, a condition that confers refractoriness to oral iron (e.g., post‐gastrectomy, celiac disease, atrophic gastritis, H. pylori infection, etc.), need for rapid anemia reversal (e.g., late in pregnancy, chronic bleeding), with erythropoietin stimulating agents (ESA) in chronic renal failure patients and as a substitute for blood transfusions in persons who refuse blood products on religious grounds. In patients on cytotoxic chemotherapy, receiving ESA, who have concomitant iron deficiency or inadequate ESA response, iron supplementation is recommended. Several studies have shown
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera